Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) Dr James Garner caught up with Proactive's Andrew Scott following the news it's been awarded US Food and Drug Administration (FDA) Fast Track Designation (FTD) for Paxalisib for the treatment of glioblastoma – the most common and aggressive form of primary brain cancer. It provides them with enhanced access to the FDA, including opportunities for face-to-face meetings and written consultation throughout the remaining development of the drug. It'll also allow what's known as a ‘rolling review’ process where Kazia can complete and submit substantial sections of its NDA filing in advance.
Kazia Therapeutics CEO hails Fast Track Designation for Paxalisib
Quick facts: Kazia Therapeutics Ltd
Price: 0.85 AUD
Market Cap: $97.88 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE